A5078457988- Pulmonary Hypertension Research and Treatments
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Liver Disease and Transplantation
- Respiratory Support and Mechanisms
- Cardiovascular Effects of Exercise
- Diet and metabolism studies
- Vascular Anomalies and Treatments
- Aortic aneurysm repair treatments
- Cardiovascular Issues in Pregnancy
- Aortic Disease and Treatment Approaches
- Ultrasound in Clinical Applications
- Heart rate and cardiovascular health
- Cardiac pacing and defibrillation studies
- Cardiomyopathy and Myosin Studies
- Hormonal Regulation and Hypertension
- Liver Disease Diagnosis and Treatment
- Iron Metabolism and Disorders
University Hospital Cologne
2020-2024
University of Cologne
2020-2024
Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify vasoresponders, for whom treatment high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate implications of response CCBs and other outcomes.
We assessed the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, in patients with heart failure preserved ejection fraction combined postcapillary precapillary pulmonary hypertension. In double-blind PASSION study (Phosphodiesterase-5 Inhibition Patients With Heart Failure Preserved Ejection Fraction Combined Post- Pre-Capillary Pulmonary Hypertension), hypertension were randomized 1:1 to receive tadalafil at target dose 40 mg or placebo. The primary end point was time...
Pulmonary arterial hypertension (PAH) is a progressive disease with limited survival. Iron deficiency (ID) correlates severity and mortality. While oral iron supplementation was shown to be insufficient in such patients, the potential impact of parenteral on clinical measures warrants further investigation.We retrospectively analysed long-term effects intravenous ferric carboxymaltose (FCM) status patients PAH ID [ferritin < 100 μg/L or ferritin 100-300 transferrin saturation (TSAT) 20%] who...
Abstract Aims In pulmonary arterial hypertension (PAH), upfront combination therapy with ERA and PDE5i is associated a reduction in morbidity mortality events improves standard haemodynamics, but data remain limited. of this study were (i) to capture detailed haemodynamic effects rapid sequential dual patients newly diagnosed PAH; (ii) monitor the impact treatment initiation on clinical variables patients' risk status, (iii) compare effect ‘classical PAH’ ‘PAH co‐morbidities’. Methods Fifty...
Guideline recommendations highlight the critical role of combination therapy for treatment pulmonary arterial hypertension (PAH). Conversely, registry data demonstrate that a considerable number PAH patients remain on monotherapy. The reasons this discrepancy elusive. aim study was to assess patient profiles, patterns, and disease characteristics diagnosed with who were kept monotherapy at experienced (PH) centres capture potential
Pulmonary hypertension is frequently underdiagnosed, and referral delayed with subsequent impact on outcomes. During the SARS-CoV-2 pandemic, restrictions daily life changes in hospitals' routine care were introduced Germany. This multi-centre study provides evidence for a negative influence of these patient pulmonary expert centres.
Background While computed tomography pulmonary angiography (CTPA) is an integral part of the work-up in patients with suspected hypertension (PH), there no established CTPA-derived prognostic marker. We aimed to assess whether quantitative readouts lung vessel morphology correlate indicators PH. Methods applied a fully-automatic in-house developed algorithm for segmentation arteries and veins determine pre-capillary PH who underwent right heart catheterization CTPA between May 2016 2019....
The recently published new European guidelines for diagnosis and treatment of pulmonary hypertension now offer the so far most extensive description genetic testing counselling arterial patients. In addition, importance a clinical screening healthy mutation carriers is highlighted as well patients with suspicion veno-occlusive disease. We frame respective parts on in context recent data provide comments. Finally, we give an outlook novel molecular approaches starting from Sotatercept,...
<b>Background:</b> Computed tomography pulmonary angiography (CTPA) is an integral part of the work-up in patients with suspected hypertension (PH). However, there no established CTPA-derived prognostic marker. <b>Aim:</b> To assess whether quantitative readouts lung vessel morphology correlate indicators. <b>Methods:</b> Patients pre-capillary PH who underwent right heart catheterization and CTPA between May 2016 2019 were enrolled this retrospective study. Lung was determined a...
Abstract Background Catalytic class IA PI 3-kinase isoform p110α is a crucial regulator of cellular proliferation and survival in numerous cell types. While critically involved pathogenic vascular remodeling, its physiological role for integrity under stress conditions has not been studied. We report protective function smooth muscle against abdominal aortic aneurysm (AAA) formation. Methods & Results In mice lacking cells (sm-p110α -/- ), perfusion the infrarenal aorta with porcine...